First-And-Only Tests Backed By Clinical Data.

99.8% NPV and 96% assay sensitivity

100% of 9-out-of-10 risk were confirmed to be affected via neonatal outcomes

Analytical sensitivity and specificity of >99.9%

100% concordance to neonatal outcomes

93.3% clinical sensitivity in 191 cases with outcome data compared to ~35% of traditional carrier screening

99.4% NPV in a high-risk population

Accurately identified all affected pregnancies as high risk at a greater than 9 in 10 risk

All unaffected pregnancies were accurately identified as low/decreased risk

The cost to detect one affected pregnancy by carrier screening with reflex to single-gene NIPT was 62% lower than traditional carrier screening

Analytical validity of single-gene NIPT with an estimated sensitivity of >98% and specificity of >99%